700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
|Marie Hlavnickova, Milan Kuchar, Hana Petrokova and Lucie Mareckova, Czech Republic|
|Keynote: J Bioprocess Biotech|
|Interleukin 17 (IL-17) and its cognate receptor (IL-17RA) play a crucial role in Th17 cell-mediated pro-inflammatory pathway and pathogenesis of several autoimmune disorders including psoriasis. Psoriasis is a chronic inflammatory skin disease with prevalence up to 3% worldwide and it is characterized by hyperplasia of the epidermis, infiltration of leukocytes into both dermis and epidermis, and dilation and growth of blood vessels. IL-17 is mainly produced by Th-17 helper cells and, via binding to its receptor, mediates IL-17-driven cell signaling in keratinocytes. Recently we have demonstrated that small protein binders derived from albumin-binding domain (ABD) scaffold can serve as useful diagnostic tools (Ahmad et al. 2012, Sipova et al. 2012, Mareckova et al. 2015) as well as efficient blockers of IL-23/IL-23 receptor interaction and modulators of IL-23/Th-17 axis on primary human leukocytes (Krizova et al. 2017, Kuchar et al. 2014). In this work we generated a collection of novel protein binders targeting human IL-17RA, called ARS ligands, using selection from highly complex ABD-derived combinatorial library in combination with ribosome display. From the group of 67 analysed ABD variants, 7 different sequence families were identified. Representatives of these groups competed with human IL-17A for binding to recombinant IL-17RA as well as to IL-17RA-IgG chimera, as tested in ELISA. Five ARS variants bind to IL-17RA-expressing THP-1 and Raji cells, as tested by flow cytometry. The four variants exhibited high-affinity binding in nanomolar range to human HaCAT cells, as measured using Ligand Tracer Green Line system. Thus, we identified several ARS inhibitory variants that will be further tested for their immunosuppressive function as novel IL-17RA antagonists.|
Petr Maly is head of Laboratory of Ligand Engineering at the Institute of Biotechnology CAS in Vestec, Czech Republic. He studied at Department of Biochemistry, Faculty of Science, Charles University in Prague, Czech Republic (1980-1985) and completed doctorate at the Institute of Molecular Genetics CAS (IMG) in Prague. He spent postdoctoral fellowship (1992-1995) at Department of Pathology and Howard Hughes Medical Institute, The University of Michigan Medical School, Ann Arbor, USA. Since 1998 to 2005 he was a research group leader at the IMG in Prague and also worked at Department of Biochemistry and Molecular Biology, College of Medicine, University of Oklahoma, USA. He also was participating investigator of Consortium for Functional Glycomics (USA, 2001–2008) and Member of Editorial Board (2001-2005) and Editor (since 2003) of the Czech journal “Biologicke listy” (Biological Letters). Since 2008, he has been working on the development of combinatorial protein libraries derived from small protein scaffolds and construction of novel high-affinity protein binders with therapeutic and diagnostic potential.
Email: [email protected]
|PDF | HTML|